122 related articles for article (PubMed ID: 36925282)
21. Coaxial dual-path electrochemical biosensing and logic strategy-based detection of lung cancer-derived exosomal PD-L1.
Liu J; Liu Z; Zhao C; Jiao Y; Li B; Shi J; Chen Z; Zhang Z
Nanoscale; 2024 May; 16(18):8950-8959. PubMed ID: 38630023
[TBL] [Abstract][Full Text] [Related]
22. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 exosomes electrochemical sensor based on coordination of AgNCs and Zr
Hu J; Mao Z; Lu Y; Chen Q; Xia J; Deng H; Chen H
Biosens Bioelectron; 2023 Sep; 235():115379. PubMed ID: 37207581
[TBL] [Abstract][Full Text] [Related]
24. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
Lux A; Kahlert C; Grützmann R; Pilarsky C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284422
[TBL] [Abstract][Full Text] [Related]
25. Construction of a cleavable linker chemistry-based
Zhou S; Li Z; Li Y; Wang X; Deng K
Anal Methods; 2023 Dec; 15(48):6738-6749. PubMed ID: 38054244
[TBL] [Abstract][Full Text] [Related]
26. Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling.
Wang C; Huang CH; Gao Z; Shen J; He J; MacLachlan A; Ma C; Chang Y; Yang W; Cai Y; Lou Y; Dai S; Chen W; Li F; Chen P
ACS Sens; 2021 Sep; 6(9):3308-3319. PubMed ID: 34494426
[TBL] [Abstract][Full Text] [Related]
27. Aptamer-based fluorescence polarization assay for separation-free exosome quantification.
Zhang Z; Tang C; Zhao L; Xu L; Zhou W; Dong Z; Yang Y; Xie Q; Fang X
Nanoscale; 2019 May; 11(20):10106-10113. PubMed ID: 31089660
[TBL] [Abstract][Full Text] [Related]
28. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
29. Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.
Fan Z; Zhou J; Shu Q; Dong Y; Li Y; Zhang T; Bai G; Yu H; Lu F; Li J; Zhao X
Biosens Bioelectron; 2024 May; 251():116104. PubMed ID: 38368644
[TBL] [Abstract][Full Text] [Related]
30. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe.
Qin X; Xiang Y; Li N; Wei B; Chen Y; Fang D; Fang M; Li Q; Liu J; Tang Y; Li X; Yang F
Biosens Bioelectron; 2022 Nov; 216():114636. PubMed ID: 35986985
[TBL] [Abstract][Full Text] [Related]
32. Immunoaffinity microflow liquid chromatography/tandem mass spectrometry for the quantitation of PD1 and PD-L1 in human tumor tissues.
Zhu Y; Zalaznick J; Sleczka B; Parrish K; Yang Z; Olah T; Shipkova P
Rapid Commun Mass Spectrom; 2020 Oct; 34(20):e8896. PubMed ID: 32666620
[TBL] [Abstract][Full Text] [Related]
33. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
34. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
[TBL] [Abstract][Full Text] [Related]
35. Programmable DNA-Fueled Electrochemical Analysis of Lung Cancer Exosomes.
Sha L; Bo B; Yang F; Li J; Cao Y; Zhao J
Anal Chem; 2022 Jun; 94(24):8748-8755. PubMed ID: 35649159
[TBL] [Abstract][Full Text] [Related]
36. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
37. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
38. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
39. Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures.
Li X; Li X; Cheng X; Bian X; Shen B; Ding X; Ding S
ACS Sens; 2022 Nov; 7(11):3571-3579. PubMed ID: 36329604
[TBL] [Abstract][Full Text] [Related]
40. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.
Domblides C; Antoine M; Hamard C; Rabbe N; Rodenas A; Vieira T; Crequit P; Cadranel J; Lavolé A; Wislez M
AIDS; 2018 Feb; 32(4):461-468. PubMed ID: 29194117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]